MetLife Investment Management’s Ingevity NGVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.41M | Sell |
19,830
-543
| -3% | -$37.1K | 0.01% | 1239 |
|
|
2025
Q4 | $1.21M | Sell |
20,373
-1,425
| -7% | -$77.3K | 0.01% | 1318 |
|
|
2025
Q3 | $1.2M | Hold |
21,798
| – | – | 0.01% | 1336 |
|
|
2025
Q2 | $939K | Hold |
21,798
| – | – | 0.01% | 1347 |
|
|
2025
Q1 | $863K | Sell |
21,798
-290
| -1% | -$12.8K | ﹤0.01% | 1436 |
|
|
2024
Q4 | $900K | Buy |
22,088
+1,206
| +6% | +$50.2K | ﹤0.01% | 1475 |
|
|
2024
Q3 | $814K | Hold |
20,882
| – | – | ﹤0.01% | 1511 |
|
|
2024
Q2 | $913K | Buy |
20,882
+1,934
| +10% | +$93.5K | 0.01% | 1386 |
|
|
2024
Q1 | $904K | Hold |
18,948
| – | – | 0.01% | 1351 |
|
|
2023
Q4 | $895K | Hold |
18,948
| – | – | 0.01% | 1356 |
|
|
2023
Q3 | $902K | Sell |
18,948
-759
| -4% | -$41.4K | 0.01% | 1285 |
|
|
2023
Q2 | $1.15M | Sell |
19,707
-20,814
| -51% | -$1.25M | 0.01% | 1196 |
|
|
2023
Q1 | $2.9M | Sell |
40,521
-423
| -1% | -$33.6K | 0.02% | 759 |
|
|
2022
Q4 | $2.88M | Sell |
40,944
-1,893
| -4% | -$133K | 0.02% | 748 |
|
|
2022
Q3 | $2.6M | Sell |
42,837
-1,514
| -3% | -$102K | 0.02% | 762 |
|
|
2022
Q2 | $2.8M | Sell |
44,351
-1,232
| -3% | -$80.3K | 0.02% | 753 |
|
|
2022
Q1 | $2.92M | Buy |
45,583
+12,791
| +39% | +$856K | 0.02% | 828 |
|
|
2021
Q4 | $2.35M | Buy |
32,792
+52
| +0.2% | +$3.96K | 0.02% | 810 |
|
|
2021
Q3 | $2.34M | Sell |
32,740
-1,015
| -3% | -$80.1K | 0.02% | 786 |
|
|
2021
Q2 | $2.75M | Sell |
33,755
-2,366
| -7% | -$190K | 0.02% | 727 |
|
|
2021
Q1 | $2.73M | Sell |
36,121
-3,165
| -8% | -$230K | 0.03% | 724 |
|
|
2020
Q4 | $2.98M | Sell |
39,286
-2,609
| -6% | -$170K | 0.03% | 625 |
|
|
2020
Q3 | $2.07M | Sell |
41,895
-840
| -2% | -$47.4K | 0.02% | 707 |
|
|
2020
Q2 | $2.25M | Buy |
42,735
+464
| +1% | +$22K | 0.03% | 663 |
|
|
2020
Q1 | $1.49M | Hold |
42,271
| – | – | 0.02% | 728 |
|
|
2019
Q4 | $3.69M | Sell |
42,271
-338
| -0.8% | -$29.6K | 0.04% | 516 |
|
|
2019
Q3 | $3.61M | Sell |
42,609
-445
| -1% | -$39.6K | 0.04% | 496 |
|
|
2019
Q2 | $4.53M | Sell |
43,054
-522
| -1% | -$52.5K | 0.05% | 397 |
|
|
2019
Q1 | $4.6M | Buy |
43,576
+25,313
| +139% | +$2.54M | 0.05% | 374 |
|
|
2018
Q4 | $1.53M | Hold |
18,263
| – | – | 0.02% | 874 |
|
|
2018
Q3 | $1.86M | Sell |
18,263
-1,098
| -6% | -$106K | 0.02% | 891 |
|
|
2018
Q2 | $1.57M | Buy |
19,361
+736
| +4% | +$58.5K | 0.02% | 869 |
|
|
2018
Q1 | $1.37M | Hold |
18,625
| – | – | 0.02% | 893 |
|
|
2017
Q4 | $1.31M | Buy |
+18,625
| New | +$1.34M | 0.01% | 929 |
|
Other funds holding NGVT
VPM
VCM
SBH
SCM
MetLife Investment Management's NGVT Position: Q1 2026 in Review
MetLife Investment Management reduced its Ingevity (NGVT) stake by 2.7% in Q1 2026, selling an estimated $37.1K and leaving 19,830 shares worth $1.41M. The position accounts for 0.01% of the portfolio, ranked #1239.
MetLife Investment Management first reported a position in NGVT in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.6M in Q1 2019. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.
- MetLife Investment Management held 19,830 shares of Ingevity worth $1.41M as of Q1 2026.
- MetLife Investment Management sold 543 Ingevity shares in Q1 2026, an estimated $37.1K.
- Ingevity made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1239 holding.
- MetLife Investment Management first reported a position in Ingevity in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Ingevity position peaked at $4.6M in Q1 2019.
- 307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.